CureVac B.V.(CVAC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CVAC CureVac B.V.

Halted 01-13 11:03:37 EST

4.66

+0.00

0.00%

High4.66	Low4.66	Vol0.00
Open4.66	D1 Closing4.66	Amplitude0.00%
Mkt Cap1.05B	Tradable Cap586.55M	Total Shares225.17M
T/O5.32M	T/O Rate0.00%	Tradable Shares125.87M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CVAC","market":"US","secType":"STK","nameCN":"CureVac B.V.","latestPrice":4.66,"timestamp":1767646800000,"preClose":4.66,"halted":3,"volume":0,"delay":0,"floatShares":125869472,"shares":225172749,"eps":0.672,"marketStatus":"Halted","change":0,"latestTime":"01-13 11:03:37 EST","open":4.66,"high":4.66,"low":4.66,"amount":5320175.482299999,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.672,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1768338000000},"marketStatusCode":2,"adr":0,"listingDate":1597377600000,"exchange":"NASDAQ","adjPreClose":4.66,"volumeRatio":0},"requestUrl":"/m/hq/s/CVAC","defaultTab":"news","newsList":[{"id":"2600055790","title":"Evotec SE Appoints Dr. Sarah Fakih as EVP, Head of Global Communications and Investor Relations","url":"https://stock-news.laohu8.com/highlight/detail?id=2600055790","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600055790?lang=en_us&edition=fundamental","pubTime":"2026-01-02 13:30","pubTimestamp":1767331817,"startTime":"0","endTime":"0","summary":"Evotec SE has appointed Dr. Sarah Fakih as Executive Vice President, Head of Global Communications and Investor Relations. In this newly created role, Dr. Fakih will lead the integrated Global Communications and Investor Relations function, reporting directly to CEO Dr. Christian Wojczewski. She succeeds Volker Braun and brings over 15 years of experience in life sciences, including senior roles at QIAGEN, MorphoSys, and CureVac.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evotec SE published the original content used to generate this news brief via ACCESS Newswire  on January 02, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260102:nNDL8qQ4PD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CVAC","BK4548","BK4139","BK4551"],"gpt_icon":0},{"id":"2592183594","title":"European Stocks Set to Close Higher in Thursday Trading; ECB Maintains 3 Key Interest Rates; England Cuts Rate by Quarter Point","url":"https://stock-news.laohu8.com/highlight/detail?id=2592183594","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592183594?lang=en_us&edition=fundamental","pubTime":"2025-12-19 00:59","pubTimestamp":1766077141,"startTime":"0","endTime":"0","summary":"European stock markets look set to close higher in Thursday trading as the Stoxx Europe was up 0.97%, Germany's DAX was advancing 0.99%, the FTSE 100 was gaining 0.69%, France's CAC was rising 0.95%, ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4551","BK4548","CVAC","BK4139"],"gpt_icon":0},{"id":"2592974910","title":"Biontech Closes Acquisition Of CureVac","url":"https://stock-news.laohu8.com/highlight/detail?id=2592974910","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592974910?lang=en_us&edition=fundamental","pubTime":"2025-12-18 18:03","pubTimestamp":1766052202,"startTime":"0","endTime":"0","summary":"Dec 18 (Reuters) - BIONTECH <22UAy.DE>::*CLOSES ACQUISITION OF CUREVAC*ABOUT 86.75% OF CUREVAC SHARES WERE TENDERED*CUREVAC WILL CONTINUE OPERATIONS IN ACCORDANCE WITH EXISTING BUSINESS PROCESSES*WILL","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nRSD6PPFGj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","BK4139","BNTX","BK4535","BK4551","BK4585","BK4588","BK4568","CVAC"],"gpt_icon":0},{"id":"2592474971","title":"BioNTech Closes Acquisition of CureVac","url":"https://stock-news.laohu8.com/highlight/detail?id=2592474971","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592474971?lang=en_us&edition=fundamental","pubTime":"2025-12-18 17:45","pubTimestamp":1766051113,"startTime":"0","endTime":"0","summary":"BioNTech has completed its acquisition of CureVac, bringing together two leading German mRNA technology firms. Approximately 86.75% of CureVac shares were tendered during the offer period, and BioNTech plans to finalize the compulsory acquisition of the remaining shares by January 2026. The transaction aims to strengthen BioNTech's capabilities in mRNA design, delivery, and manufacturing, supporting its oncology strategy and expanding its portfolio of mRNA-based therapeutics. CureVac will continue to operate under its existing organizational processes as BioNTech conducts further strategic and operational analyses to define the future setup.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioNTech SE published the original content used ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nNDL8pJQBr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","BK4585","SG9999014005.SGD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","NDAQ","SG9999014021.USD","BK4588","BK4139","SG9999014039.USD","LU2210149790.SGD","LU2095319765.USD","LU0314104364.USD","BK4568","IE00BGHQF748.EUR","BK4551","BK4548","SG9999014013.SGD","LU2210150020.SGD","BNTX","BK4535","CVAC","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2592917009","title":"CureVac Down Over 12%, on Pace for Largest Percent Decrease in Almost Two Years -- Data Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2592917009","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592917009?lang=en_us&edition=fundamental","pubTime":"2025-12-18 02:57","pubTimestamp":1765997820,"startTime":"0","endTime":"0","summary":"CureVac N.V.  is currently at $4.22, down $0.61 or 12.55%. --Would be lowest close since June 11, 2025, when it closed at $4.07. --On pace for largest percent decrease since Dec. 19, 2023, when it fell 29.55%. --Currently down four consecutive days; down 17.68% over this period. --Longest losing streak since Nov. 21, 2025, when it fell for four straight trading days. --Worst four day stretch since the four days ending June 20, 2024, when it fell 18.5%. --Up 23.61% year-to-date; on pace for best year on record . --Up 53.27% from 52 weeks ago , when it closed at $2.75. --Down 24.73% from its 52-week closing high of $5.60 on June 12, 2025. --Up 62.74% from its 52-week closing low of $2.59 on April 4, 2025. --Down 13.59% at today's intraday low; largest intraday percent decrease since Jan. 8, 2025, when it fell as much as 17.31%","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CVAC","BK4551","BK4548","BK4139"],"gpt_icon":0},{"id":"2588386044","title":"BioNTech Secures 81.7% of CureVac Shares in Tender Offer","url":"https://stock-news.laohu8.com/highlight/detail?id=2588386044","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588386044?lang=en_us&edition=fundamental","pubTime":"2025-12-03 22:01","pubTimestamp":1764770473,"startTime":"0","endTime":"0","summary":"BioNTech is proceeding with an offer to exchange American Depositary Shares  for shares of CureVac. The offer has commenced, and relevant documents including an exchange offer prospectus and related materials have been filed with the U.S. Securities and Exchange Commission. CureVac has also submitted a recommendation statement regarding the offer.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioNTech SE published the original content used to generate this news brief via GlobeNewswire  on December 03, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nNDLb9w6jL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","BK4535","BK4585","IE00B64PRP62.GBP","CVAC","BK4548","BK4551","LU2210150020.SGD","BK4568","BK4112","LU2095319765.USD","BK4588","LU2210149790.SGD","IE00BKPKM429.USD","LU0314104364.USD","BK4139","IE00BGHQF748.EUR","BNTX","NDAQ"],"gpt_icon":0},{"id":"2588741058","title":"Can New Board Leadership at CureVac (CVAC) Shift the Narrative After Recent Earnings Decline?","url":"https://stock-news.laohu8.com/highlight/detail?id=2588741058","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588741058?lang=en_us&edition=fundamental","pubTime":"2025-12-01 12:28","pubTimestamp":1764563312,"startTime":"0","endTime":"0","summary":"CureVac N.V. recently held an Extraordinary General Meeting where shareholders approved the conditional appointment of Ramón Zapata Gomez as managing director, alongside Sierk Poetting, James Ryan, and Annemarie Hanekamp as supervisory directors.\nShortly before these board changes, CureVac reported sharply lower sales and net income for the third quarter and nine months ended September 30, 2025, compared to the previous year.\nWith earnings showing substantial declines, we will examine how...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cvac/curevac/news/can-new-board-leadership-at-curevac-cvac-shift-the-narrative","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cvac/curevac/news/can-new-board-leadership-at-curevac-cvac-shift-the-narrative","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CVAC"],"gpt_icon":0},{"id":"2586625283","title":"BioNTech Says CureVac Shareholders Are Advised To Tender Their Shares By 6:00 P.M. Eastern Time On Tuesday, December 2, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2586625283","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586625283?lang=en_us&edition=fundamental","pubTime":"2025-11-26 20:45","pubTimestamp":1764161109,"startTime":"0","endTime":"0","summary":"Nov 26 (Reuters) - BIONTECH SE <22UAy.DE>::*ANNOUNCED APPROVAL OF MATTERS RELATING TO EXCHANGE OFFER ( \"OFFER\") FOR ALL OUTSTANDING SHARES OF CUREVAC N.V. (NASDAQ: CVAC, \"CUREVAC\") AT EXTRAORDINARY GE","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nRSD4RM6k7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4568","BK4551","BK4139","BK4548","BK4535","BNTX","CVAC","BK4588"],"gpt_icon":0},{"id":"2586254782","title":"BioNTech shares update on exchange offer for CureVac shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2586254782","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586254782?lang=en_us&edition=fundamental","pubTime":"2025-11-26 20:35","pubTimestamp":1764160532,"startTime":"0","endTime":"0","summary":"BioNTech (BNTX) announced the approval of matters relating to the exchange offer for all outstanding shares of CureVac (CVAC) at the extraordinary ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/biontech-shares-update-on-exchange-offer-for-curevac-shares-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/biontech-shares-update-on-exchange-offer-for-curevac-shares-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4535","BK4548","BK4588","BNTX","BK4551","BK4139","CVAC","BK4568","BK4585"],"gpt_icon":0},{"id":"2586407772","title":"CureVac NV Held Extraordinary General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2586407772","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586407772?lang=en_us&edition=fundamental","pubTime":"2025-11-26 07:48","pubTimestamp":1764114509,"startTime":"0","endTime":"0","summary":"CureVac NV held an Extraordinary General Meeting on November 25, 2025. Shareholders approved all proposals related to BioNTech SE's public exchange offer for all outstanding shares in CureVac. The meeting approved the legal merger of CureVac with CureVac Merger B.V., with new shares issued to shareholders. Approval was also given for the subsequent sale and transfer of all outstanding shares in CureVac SE to BioNTech SE and the cancellation of all outstanding class A shares in CureVac Merger B.V. Additionally, the conditional release of managing directors from liability for the exercise of their duties was approved.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nNDL6rtQkz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4551","BNTX","BK4568","BK4585","BK4139","BK4588","BK4535","CVAC","BK4548"],"gpt_icon":0},{"id":"2585980554","title":"Nasdaq Surges 350 Points; Enlivex Therapeutics Shares Spike Higher","url":"https://stock-news.laohu8.com/highlight/detail?id=2585980554","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585980554?lang=en_us&edition=fundamental","pubTime":"2025-11-24 22:47","pubTimestamp":1763995637,"startTime":"0","endTime":"0","summary":" ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/25/11/49030696/nasdaq-surges-350-points-enlivex-therapeutics-shares-spike-higher","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QLD","BK4122","BK4006","BK4539","BK4548","TWNP","CLSDQ","NVIW.SI","TQQQ","QID","USJW.SI","INHD","BK4209",".IXIC","TSYW.SI","BK4139","BK4007","LENZ","IVP","PCOM","USAW.SI","NQmain","CVAC","BK4185","CLSD","MNQmain","ENLV","PSQ","SQQQ","BK4551","PMN"],"gpt_icon":1},{"id":"2585462271","title":"CureVac Q3 EPS $1.41 Beats $(0.17) Estimate, Sales $63.295M Beat $14.520M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2585462271","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585462271?lang=en_us&edition=fundamental","pubTime":"2025-11-24 21:18","pubTimestamp":1763990295,"startTime":"0","endTime":"0","summary":"CureVac (NASDAQ:CVAC) reported quarterly earnings of $1.41 per share which beat the analyst consensus estimate of $(0.17) by 929.41 percent. This is a 687.5 percent increase over losses of $(0.24) per share from the same","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/49028468/curevac-q3-eps-1-41-beats-0-17-estimate-sales-63-295m-beat-14-520m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CVAC","BK4139","BK4548","BK4551"],"gpt_icon":0},{"id":"2585746247","title":"Update: CureVac Q3 Earnings, Revenue Fall; German Regulators Clear BioNTech Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2585746247","media":"MT Newswires Live","labels":["corporation","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585746247?lang=en_us&edition=fundamental","pubTime":"2025-11-24 21:12","pubTimestamp":1763989961,"startTime":"0","endTime":"0","summary":"CureVac  reported Q3 earnings Monday of 1.21 euros  per diluted share, down from 1.50 euros a year earlier.Revenue for the quarter ended Sept. 30 was 54.1 million euros, down from 493.9 million euros a year earlier.Two analysts polled by FactSet expected 21.4 million euros.The decline in revenue was primarily driven by the absence of a one-time revenue of 480.4 million euros recognized in Q3 2024 in connection with the new license agreement with GlaxoSmithKline Biologicals.As of Sept. 30, the company said it had 416.1 million euros in cash and cash equivalents. It also reaffirmed its expected cash runway into 2028.CureVac said the German Federal Cartel Office has approved BioNTech's  planned acquisition of the company, a key step in completing the deal later this year.BioNTech's public exchange offer for all CureVac's shares will run until Dec. 3, the company said, adding that it has scheduled an extraordinary general meeting of shareholders on Tuesday in connection with the offer.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4551","BK4139","BNTX","BK4548","BK4535","BK4585","BK4588","CVAC","BK4568"],"gpt_icon":0},{"id":"2585462699","title":"CureVac reports Q3 EPS EUR 1.21 vs. EUR 1.51 last year","url":"https://stock-news.laohu8.com/highlight/detail?id=2585462699","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585462699?lang=en_us&edition=fundamental","pubTime":"2025-11-24 20:55","pubTimestamp":1763988943,"startTime":"0","endTime":"0","summary":"07:50 EST CureVac (CVAC) reports Q3 EPS EUR 1.21 vs. EUR 1.51 last year Published first on TheFly – the ultimate source for real-time, market-movin...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/curevac-reports-q3-eps-eur-1-21-vs-eur-1-51-last-year-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/curevac-reports-q3-eps-eur-1-21-vs-eur-1-51-last-year-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CVAC","BK4551","BK4139","BK4548"],"gpt_icon":0},{"id":"2585649264","title":"Earnings Flash (CVAC) CureVac Posts Q3 EPS 1.21 Euros","url":"https://stock-news.laohu8.com/highlight/detail?id=2585649264","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585649264?lang=en_us&edition=fundamental","pubTime":"2025-11-24 20:40","pubTimestamp":1763988055,"startTime":"0","endTime":"0","summary":"Earnings Flash (CVAC) CureVac Posts Q3 EPS 1.21 Euros","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CVAC"],"gpt_icon":0},{"id":"2585464827","title":"BioNTech Offer for CureVac Shares Enters Final Phase After Regulatory Clearance","url":"https://stock-news.laohu8.com/highlight/detail?id=2585464827","media":"Reuters","labels":["shareholding","policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585464827?lang=en_us&edition=fundamental","pubTime":"2025-11-24 20:30","pubTimestamp":1763987443,"startTime":"0","endTime":"0","summary":"BioNTech's planned acquisition of CureVac took a step forward as the German Federal Cartel Office granted clearance for the transaction first announced in June 2025. The offer period for BioNTech's public exchange offer for all outstanding CureVac N.V. shares began on October 21, 2025, and is scheduled to close on December 3, 2025. An Extraordinary General Meeting of CureVac shareholders has been scheduled for November 25, 2025, as both companies aim to accelerate the development of innovative mRNA-based therapies.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CureVac NV published the original content used to generate this news brief via ACCESS Newswire  on November 24, 2025, and is solely responsible for the information contained the","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nNDL4VJdNj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CVAC","BK4585","BK4548","BK4139","BNTX","BK4588","BK4568","BK4551","BK4535"],"gpt_icon":0},{"id":"2585746103","title":"Curevac Reaffirms Its Expected Cash Runway Into 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2585746103","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585746103?lang=en_us&edition=fundamental","pubTime":"2025-11-24 20:23","pubTimestamp":1763987014,"startTime":"0","endTime":"0","summary":"Nov 24 (Reuters) - CUREVAC NV <5CV.DE>::*CUREVAC Q3 REVENUE EUR 54.1 MILLION VERSUS. IBES ESTIMATE EUR 3.34 MILLION*CUREVAC Q3 EBIT EUR 310.2 MILLION*CUREVAC NV - COMPANY REAFFIRMS ITS EXPECTED CASH R","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nRSDbD80bt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","BK4548","BNTX","BK4585","CVAC","BK4568","BK4588","BK4551","BK4139"],"gpt_icon":0},{"id":"2585461140","title":"CureVac NV reports Q3 net profit of €273.2 million and nine-month net profit of €161.6 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2585461140","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585461140?lang=en_us&edition=fundamental","pubTime":"2025-11-24 20:13","pubTimestamp":1763986402,"startTime":"0","endTime":"0","summary":"CureVac NV reported a net profit of 273.2 million for the third quarter of 2025, down from 338.0 million in the same period of 2024. Net profit for the first nine months of 2025 was 161.6 million, compared to 194.9 million in the prior-year period. The net financial result showed a loss of 2.6 million for the third quarter of 2025, compared to a gain of 2.2 million in the previous year, mainly due to unrealized foreign exchange losses. Basic and diluted earnings per share for the third quarter were 1.21, compared to 1.51 and 1.50 respectively in 2024. For the first nine months, basic earnings per share were 0.72 and diluted earnings per share were 0.71, down from 0.87 and 0.86 in the previous year. Revenues were 54.1 million for the third quarter and 56.3 million for the first nine months of 2025. Business developments included clearance from the German Federal Cartel Office for the planned BioNTech-CureVac transaction and the start of BioNTech's public exchange offer for all outstandi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nNDL6dTwrC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","BNTX","CVAC","BK4568","BK4585","BK4139","BK4551","BK4588","BK4535"],"gpt_icon":0},{"id":"2585461192","title":"CureVac Nv - Company Reaffirms Its Expected Cash Runway Into 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2585461192","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585461192?lang=en_us&edition=fundamental","pubTime":"2025-11-24 20:10","pubTimestamp":1763986247,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nPLX35A581:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4551","CVAC","BK4548","BK4139"],"gpt_icon":0},{"id":"2585197461","title":"CureVac Nv - Net Financial Result for Three and Nine Months Ended September 30, 2025, Was Loss of EUR 2.6 Mln and Gain of EUR 2.2 Mln, Respectively","url":"https://stock-news.laohu8.com/highlight/detail?id=2585197461","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585197461?lang=en_us&edition=fundamental","pubTime":"2025-11-24 20:10","pubTimestamp":1763986247,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nPLX35A581:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4548","CVAC","BK4551"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.curevac.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":-0.0772},{"period":"3month","weight":-0.1306},{"period":"6month","weight":-0.1496},{"period":"1year","weight":0.1069},{"period":"ytd","weight":0.031}],"compareEarnings":[{"period":"1week","weight":0.0108},{"period":"1month","weight":0.0197},{"period":"3month","weight":0.0497},{"period":"6month","weight":0.1136},{"period":"1year","weight":0.1975},{"period":"ytd","weight":0.0194}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer therapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.073407},{"month":2,"riseRate":0.2,"avgChangeRate":-0.099557},{"month":3,"riseRate":0.2,"avgChangeRate":-0.055603},{"month":4,"riseRate":0.6,"avgChangeRate":0.064149},{"month":5,"riseRate":0.8,"avgChangeRate":0.233107},{"month":6,"riseRate":0.4,"avgChangeRate":-0.089668},{"month":7,"riseRate":0.2,"avgChangeRate":-0.076476},{"month":8,"riseRate":0.2,"avgChangeRate":-0.023047},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.136579},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.099323},{"month":11,"riseRate":0.833333,"avgChangeRate":0.241614},{"month":12,"riseRate":0.166667,"avgChangeRate":-0.149134}],"exchange":"NASDAQ","name":"CureVac B.V.","nameEN":"CureVac B.V."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CureVac B.V.(CVAC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest CureVac B.V.(CVAC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"CureVac B.V.,CVAC,CureVac B.V.股票,CureVac B.V.股票老虎,CureVac B.V.股票老虎国际,CureVac B.V.行情,CureVac B.V.股票行情,CureVac B.V.股价,CureVac B.V.股市,CureVac B.V.股票价格,CureVac B.V.股票交易,CureVac B.V.股票购买,CureVac B.V.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CureVac B.V.(CVAC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest CureVac B.V.(CVAC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction